- Published at
- by manilatimes.net
positive
positive
News for Revive Therapeutics Ltd. (RVVTF)
- Published at
- by gurufocus.com
negativenegativeRevive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment | RVVTF Stock News
Revive Therapeutics (RVVTF) to explore Bucillamine's potential in cancer treatment. Partnership with U.S. University Cancer Institute and Defence R&D Ca- Published at
- by gurufocus.com
positivepositiveRevive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (”Revive” or the ”Company”) ( RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveRevive Therapeutics Announces Results of Annual Shareholder Meeting
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (”Revive” or the ”Company”) ( RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty lif- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveRevive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- TORONTO, March 3, 2025 ”“ Revive Therapeutics Ltd. (”Revive” or the ”Company”) ( RVVTF) (CSE: RVV) (FRANK- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositiveRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life science…- Published at
- by financialpost.com
positivepositiveRevive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life science…- Published at
- by financialpost.com
positivepositiveRevive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
TORONTO, June 10, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life science…- Published at
- by marketscreener.com
neutralneutralRevive Therapeutics : Document
Corporate Fact Sheet Q2-2024 OVERVIEW Developing novel therapeutics and...- Published at
- by financialpost.com
positivepositiveRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life…- Published at
- by marketscreener.com
neutralneutralRevive Therapeutics : Document -March 20, 2024 at 12:18 pm EDT
Corporate Fact Sheet Q1-2024 OVERVIEW Developing novel therapeutics and...- Published at
- by financialpost.com
negativenegativeRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN- Published at
- by financialpost.com
positivepositiveRevive Therapeutics Explores the Use of Bucillamine for Long COVID
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life…- Published at
- by prnewswire.com
mixedmixedExtremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment
/PRNewswire/ -- DelveInsight's 'COVID-19 Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...- Published at
- by benzinga.com
mixedmixed- Published at
- by prnewswire.com
mixedmixedGlobal COVID-19 Therapeutics Market worth $14.6 billion by 2022 - Exclusive Report by InsightAce Analytic
/PRNewswire/ -- The newly published report titled "Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline...